Skip to main content

Bausch Health Value Stock - Dividend - Research Selection

Bausch Health Companies Inc.

ISIN: CA0717341071, WKN: A2JQ1X

Market price date: 08.01.2021
Market price: 23,06 USD




Bausch Health Companies Inc. Fundamental data and company key figures of the share

Annual reports in USD
Key figures 23-02-2020
Cash flow
Net operating cash flow 1.501.000.000
Capital Expenditures -503.000.000
Free cash flow 998.000.000
Balance sheet
Total Equity 1.063.000.000
Liabilities & Shareholders equity 33.863.000.000
Income statement
Net income -1.788.000.000
Eps (diluted) -5,080
Diluted shares outstanding 704.200.000
Net sales/revenue 8.601.000.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI-5,28
ROE3,14
Income statement
P/E-4,54
Div. Yield0,00%
P/B0,00
P/S1,89


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBHC
Market Capitalization16.238.852.096,00 USD
CountryCanada
IndicesS&P/TSX 60
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-10-16,2.0000/1.0000; 2000-10-05,2.000000/1.000000; 2000-01-20,2.0000/1.0000; 1996-01-17,3.0000/1.0000
Internetwww.valeant.com


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.valeant.com